Affiliation:
1. Mekelle University
2. University of Global Health Equity
3. University of Algarve
Abstract
Abstract
Background: Statin-induced myopathy is reported to be associated with the solute carrier organic anion transporter family member 1B1 gene single nucleotide polymorphism, c.521T>C. There is no epidemiologic data on this gene polymorphism in several countries. Therefore, this study aimed at assessing the genotype and allele frequencies of the gene variant in three countries.
Methods: This study involved healthy individuals from Colombia, Mozambique, and Portugal. Genomic DNA was isolated from blood samples using the Qiamp DNA Extraction Kit (Qiagen). The isolated DNA was genotyped using novel Polymerase Chain Reaction (PCR) - Restriction Fragment Length Polymorphism. Microstat and GraphPad quick cal software were used for the Chi-square test and evaluation of Hardy-Weinberg equilibrium respectively.
Results: A total of 181 individuals’ blood sample was analyzed. Overall, TT (74.0%) genotype was the highest and CC (7.8%) was the lowest. Country wise genotypic frequencies were Colombia 47(70.2%) TT, 12(17.9%) TC and 8(11.9%) CC; Mozambique 47(88.7%) TT, 5(9.4%) TC, and 1(1.9%) CC; and Portugal 40(65.6%) TT, 16(26.2%) TC, and 5(8.2%) CC. The reference (T) allele was highest among Mozambicans (93.4%) compared to Colombians (79.1%) and Portuguese (78.7%). Mozambicans showed statistically significant genotypic and allelic frequency differences compared to Colombians (p<0.01) and Portuguese (p <0.01).
Conclusions: Overall and country-wise, CC genotype was less frequent and it is relatively high for Colombians and Portuguese populations. This finding may imply statins risk-benefit variability associated with CC genotype among these populations that needs further understanding.
Publisher
Research Square Platform LLC
Reference25 articles.
1. European Medicines Agency. Terminology in pharmacogenetics. EMA. October 21., 2002. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-terminology-pharmacogenetics_en.pdf. Accessed September 14, 2019.
2. Ho R, Kim R. Transporters and drug therapy: implications for drug disposition and disease.Clin. Pharmacol Ther.2005;78, 260 – 77.
3. Transporter pharmacogenetics and statin toxicity;Niemi M;Clin Pharmacol Ther,2010
4. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans;Tirona R;J Biol Chem,2001
5. Simple Alkaline Extraction of Human Genomic DNA from Whole Blood, Buccal Epithelial Cells, Semen and Forensic Stains for PCR;Rudbeck L;Biotechniques,1998